Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00048945

Enrollment

820

Registered

2002-11-14

Start date

2002-01-31

Completion date

2004-10-31

Last updated

2017-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B

Brief summary

The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.

Interventions

DRUGPEGASYS

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of hepatitis B * Not pregnant

Exclusion criteria

* Treatment for hepatitis B in past 6 months * Other hepatitis infections * Severe liver disease * Pregnancy

Countries

Australia, Brazil, Canada, China, France, Germany, Israel, New Zealand, Poland, Puerto Rico, Singapore, South Korea, Switzerland, Taiwan, Thailand, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026